ArticleAmerican journal of translational research2026
LncRNA EWSAT1 promotes colorectal cancer progression by regulating the miR-330-5p/CPEB4 axis.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ewing sarcoma-associated transcript 1 (EWSAT1) has been implicated in colorectal cancer (CRC) progression, but its downstream regulatory mechanisms remain unclear. This study aimed to investigate whether EWSAT1 promotes the malignant progression of CRC via the miR-330-5p/CPEB4 axis. The expression levels of EWSAT1, miR-330-5p, and CPEB4 in 30 pairs of CRC tissues and adjacent normal tissues were detected by qRT-PCR. The effects of siRNA-mediated EWSAT1 knockdown on cell proliferation, migration, invasion, and apoptosis were evaluated in HCT-15 and HCT-116 cells. RNA pull-down and dual-luciferase reporter assays were performed to verify the interactions between EWSAT1 and miR-330-5p, as well as between miR-330-5p and the 3'-UTR of CPEB4. Additionally, qRT-PCR, Western blot analysis, and rescue assays (via miR-330-5p inhibition or CPEB4 overexpression) were employed to clarify the functional role of this regulatory axis. The expression levels of EWSAT1 and CPEB4 were increased, while that of miR-330-5p was decreased in CRC tissues compared with adjacent normal tissues. Knockdown of EWSAT1 significantly inhibited the proliferation, migration, and invasion of CRC cells, and promoted their apoptosis. Mechanistically, EWSAT1 could directly bind to miR-330-5p, thereby alleviating the inhibitory effect of miR-330-5p on CPEB4. Inhibition of miR-330-5p or overexpression of CPEB4 could partially reverse the suppression of malignant phenotypes induced by EWSAT1 knockdown. Furthermore, high CPEB4 expression was associated with poorer survival outcomes in CRC patients. In conclusion, EWSAT1 promotes the malignant phenotypes of CRC cells by regulating the miR-330-5p/CPEB4 axis. This molecular axis may provide new insights into the mechanisms of CRC progression and potential targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.